The combination therapy pairs eloralintide, an experimental amylin receptor agonist, with tirzepatide, the active ingredient in Lilly’s approved GIP/GLP-1 medication marketed as Zepbound for obesity and Mounjaro for diabetes. At the most potent dosing regimen-eloralintide 9 mg combined with Zepbound 15 mg-patients experienced an average weight reduction of 54.1 pounds from baseline at 48 weeks. The study also demonstrated meaningful metabolic benefits beyond weight reduction, with eloraTZP cutting blood sugar levels by lowering A1C by up to 2.9% compared to 2.4% for tirzepatide administered alone.

Significance for Diabetic Obesity Treatment

The results presented at the 62nd annual meeting of the European Association for the Study of Diabetes in Milan, Italy carry particular weight because patients with type 2 diabetes typically experience attenuated responses to obesity medications. Kenneth Custer, president of Lilly’s cardiometabolic health division, stated in an interview that he expected the combination drug would offer the best balance of efficacy, safety, and tolerability within Lilly’s obesity portfolio and among competitors. Analysts at Citi noted in a Wednesday client communication that the 23.3% average weight loss figure is both comparable to tirzepatide performance in patients without type 2 diabetes and notable given the efficacy attenuation typically seen with diabetes.

The achievement exceeded Citi analyst expectations, with the results from the highest combination dose coming in comfortably above their 17% weight loss benchmark. Geoff Meacham, an analyst at Citi, emphasized that the findings provide strong combination proof-of-concept and broaden Lilly’s cardiometabolic portfolio beyond today’s incretin standards. Custer suggested it was possible the combination could lead to even greater weight loss in later trials than retatrutide, another promising Lilly experimental obesity medication that drove average weight reduction of up to 28.3% over 80 weeks in patients without diabetes in a late-stage trial.

Triple-Hormone Mechanism of Action

Lilly developed eloraTZP to activate three nutrient-stimulated hormones: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and amylin. These hormones function as key metabolic and hormone regulators produced in the gut and pancreas to control blood sugar, digestion, and appetite. Amylin, which is co-secreted with insulin by pancreatic beta-cells, has gained increasing attention recently as an obesity drug target because it works to slow digestion, block excess sugar production, and acts on the brain to signal satiety after eating.

The mid-stage study enrolled 367 adults with obesity or overweight and type 2 diabetes, testing eloraTZP at different doses, plus each drug administered independently, against placebo. Lilly based its interpretation on the efficacy estimand, which represents the efficacy had all randomized participants taken their study treatment as directed for 48 weeks. Based on the positive readout, Lilly plans to initiate phase 3 trials with eloraTZP in 2026’s fourth quarter, moving the experimental therapy closer to potential regulatory approval and commercial availability.

Safety Profile and Discontinuation Concerns

Despite the strong efficacy data, Lilly shares fell marginally as investors focused on adherence patterns and long-term persistence challenges associated with the dual-drug regimen. Patients discontinued eloraTZP treatment at rates ranging from 10.8% to 27%, depending on the severity of side effects as multiple doses were tested throughout the trial. That discontinuation range compared with a dropout rate of 0% to 10.8% with eloralintide administered alone, 2.9% for tirzepatide monotherapy, and 16.7% for participants who received placebo injections.

“The outsized weight loss benefit is being questioned relative to the discontinuation rates and the reality that this is a dual-drug regime,” said Kevin Gade, COO at Bahl & Gaynor, which holds Lilly shares.

The most common side effects documented in the trial were mild to moderate gastrointestinal issues that occurred mainly during dose escalation and were more frequent in the combination treatment arms. These tolerability patterns mirror those seen with other incretin-based obesity medications, though the higher discontinuation rates at certain dose levels may prompt Lilly to optimize dosing strategies before advancing to phase 3 development.

Competitive Landscape in Obesity Therapeutics

The eloraTZP data emerge as Lilly intensifies its competition with Novo Nordisk for leadership in the multibillion-dollar obesity treatment market. Lilly reported topline data from a phase 3 retatrutide trial in July, with full results also presented this week at the EASD meeting showing that 34.9% of patients given retatrutide 12 mg lost at least 25% of their body weight. The pharmaceutical giant’s expanding obesity pipeline now includes multiple mechanisms of action, positioning the company to potentially offer differentiated treatment options for diverse patient populations with varying metabolic profiles and comorbid conditions.

The combination approach represents a strategic bet that activating multiple hormonal pathways simultaneously will deliver superior outcomes compared to single-mechanism therapies. By pairing its approved tirzepatide franchise with the experimental amylin agonist, Lilly aims to address the substantial unmet need among patients with both obesity and type 2 diabetes-a population that historically responds less robustly to weight-loss interventions. The forthcoming phase 3 program will provide definitive evidence on whether eloraTZP can maintain its efficacy advantage in larger, more diverse patient cohorts while demonstrating an acceptable safety and tolerability profile for chronic administration.

The post Eli Lilly’s Combination Obesity Drug Achieves 23% Weight Loss in Diabetic Patients, Surpassing Zepbound appeared first on The Daily Update.

CVS Health announced Thursday it will restore coverage for Eli Lilly’s weight-loss drug Zepbound on select formularies. The pharmacy giant will add the treatment as a co-preferred option alongside rival Novo Nordisk’s Wegovy. This marks a significant reversal from last year’s exclusive agreement. The decision aims to give employers and health plans better access to GLP-1 weight-loss treatments. Additionally, CVS plans to offer more affordable options for patients seeking obesity care.

Zepbound will return to CVS Caremark’s commercial formularies on October 1. Caremark, the pharmacy benefit management unit of CVS, had dropped the drug on July 1 last year. CVS secured more favorable pricing from the Danish drugmaker through negotiations. This deal initially made Wegovy the sole preferred obesity treatment on standard plans.

The expanded coverage may benefit up to 30 million Americans on standard commercial plans. Plan sponsors adopting Caremark’s standard formulary template gain new flexibility. However, these sponsors can still opt out of covering GLP-1 drugs for weight loss. Coverage of both Lilly’s and Novo’s treatments isn’t guaranteed for all patients.

New Obesity Pill Joins Coverage Options

CVS will also remove a new-to-market block on Lilly’s recently launched oral pill, Foundayo. The change becomes effective June 1 for plans that approve the drug. A new-to-market block restricts coverage on newly FDA-approved medications. Insurers and pharmacy benefit managers use this policy to evaluate new drugs before adding coverage.

The oral pill represents a significant advance in obesity treatment. This allows patients to choose between injections and pills for weight management. Lilly confirmed that Foundayo will now be covered by all three major pharmacy benefit managers. The drugmaker celebrated the expanded access in a statement Thursday.

“With this expanded coverage, millions of Americans will have access to Zepbound and Foundayo,” Lilly stated. The company emphasized giving patients and doctors real choice in obesity treatment. Lilly pledged to continue working toward universal access. The pharmaceutical giant aims to make these medications available to everyone who needs them.

Competition Drives Down GLP-1 Costs

CVS expects the dual-preferred strategy to drive 10% to 15% additional savings across the weight management category. The healthcare giant touted last year’s exclusive Novo Nordisk agreement as groundbreaking. CVS became the first major pharmacy benefit manager to spur competition in the GLP-1 market. The move successfully helped “bend the cost curve” for expensive obesity medications.

Both Lilly and Novo responded by partnering with CVS on pricing. The healthcare company pointed to successful continued pricing negotiations with both drugmakers. These discussions made the dual-coverage model financially viable for insurers and employers. The competitive pressure motivated both manufacturers to reduce prices significantly.

According to Ed DeVaney, CVS Caremark’s president, the company took a proactive approach to negotiations. This strategy improved affordability and access for customers and their members. The pharmacy benefit manager leveraged its massive purchasing power effectively. Caremark serves as one of the nation’s largest pharmacy benefit managers.

Industry Faces Growing GLP-1 Cost Pressures

The increasing popularity and high prices of GLP-1 drugs have created challenges for employers. Some health plans have limited or dropped coverage for weight-loss use entirely. CVS previously acknowledged that many clients discontinued coverage of GLP-1 drugs for obesity. The financial burden of these medications strained insurance budgets across the industry.

The pharmacy benefit manager system plays a crucial role in drug pricing, negotiating rebates and fees with manufacturers. Additionally, they reimburse pharmacies for patients’ prescriptions. These organizations create formularies listing medications covered by insurance plans. The system determines which drugs patients can access at affordable copayments.

Pharmacy benefit managers negotiate rebates and fees directly with drug manufacturers. They maintain significant influence over which medications gain widespread coverage. Their decisions affect millions of patients’ treatment options nationwide. The organizations serve as crucial intermediaries between drugmakers, insurers, and patients.

Novo Nordisk Maintains Competitive Position

Novo Nordisk expressed satisfaction with the new arrangement in a statement. The company noted that Wegovy injection and newly launched pill retain preferred status on CVS formularies. Caremark patients can remain on those drugs without interruption. The Danish pharmaceutical company maintains strong market position despite sharing preferred status.

The dual-preferred model puts both companies on equal footing in major drug plans. This arrangement benefits Lilly’s efforts to maintain dominance in the blockbuster weight-loss market. Previously, patients on standard plans faced higher out-of-pocket costs for Zepbound. Some needed to navigate additional hurdles to obtain Lilly’s drug instead of Wegovy.

Model May Reshape Specialty Drug Coverage

The competitive model may become an industry standard for managing expensive specialty medications. This approach, which balances manufacturer competition with patient access needs, could reshape drug coverage. Other insurers might adopt similar dual-preferred strategies for different drug categories. The success of CVS’s approach could influence broader pharmacy benefit management practices.

The GLP-1 market continues expanding rapidly as demand for obesity treatments grows. Both Lilly and Novo Nordisk have invested heavily in manufacturing capacity. The companies race to meet surging patient demand for weight-loss medications. Supply constraints have periodically limited access to these blockbuster drugs.

The restored coverage marks a significant victory for Eli Lilly and patients seeking treatment options. The pharmaceutical company regains access to millions of potential customers through Caremark formularies. Patient choice increases substantially with both major GLP-1 treatments covered equally. Doctors can now prescribe based on clinical factors rather than insurance restrictions.

The post CVS Health Restores Zepbound Coverage After Landmark Pricing Deal appeared first on The Daily Update.

Eli Lilly announced positive topline results from TRIUMPH-1, a pivotal Phase 3 clinical trial. The study evaluated retatrutide, an investigational triple hormone receptor agonist. Participants with obesity or overweight conditions achieved remarkable weight reductions. The trial marks a significant advance in metabolic disease treatment. Results demonstrate the power of multi-pathway hormonal intervention.

The 12 mg dose produced the most dramatic outcomes. Participants lost an average of 70.3 pounds over 80 weeks. This represented a 28.3% reduction from baseline weight. Nearly half of participants on the highest dose achieved exceptional results. Specifically, 45.3% reached at least 30% body weight reduction. These levels historically associate with bariatric surgery outcomes.

Retatrutide represents a first-in-class medication targeting three distinct pathways. The drug activates GIP, GLP-1, and glucagon receptors simultaneously. This triple mechanism distinguishes it from existing obesity treatments. Eli Lilly currently markets Zepbound (tirzepatide) and Foundayo (orforglipron). Retatrutide potentially offers superior efficacy through its unique approach.

Trial Design and Participant Demographics

TRIUMPH-1 enrolled 2,339 adults across multiple sites. All participants had obesity or overweight status. Each had at least one weight-related comorbidity. Critically, none had diabetes at enrollment. The trial ran for 80 weeks under double-blind, placebo-controlled conditions.

Researchers randomized participants into four equal groups. Three groups received retatrutide at different doses. The fourth group received placebo for comparison. Treatment began at 2 mg once weekly. Doses escalated every four weeks. Participants reached target levels gradually. This approach helped manage tolerability. It allowed patients to adjust to increasing medication levels.

Average baseline weight measured 112.7 kilograms (approximately 248 pounds). Mean body mass index stood at 40.0. These figures represent severe obesity classifications. Participants faced significant health risks from excess weight. The cohort reflected real-world obesity treatment populations.

Comprehensive Results Across All Dose Levels

Every dose of retatrutide met the primary endpoint. All three treatment arms demonstrated clinically meaningful weight loss. The 4 mg dose achieved an average reduction of 47.2 pounds. This represented 19.0% body weight loss at 80 weeks. Remarkably, this dose required only one escalation step.

The 4 mg cohort showed additional advantages. Discontinuation rates due to adverse events remained lower. Compared to placebo, tolerability appeared favorable. This dose may suit patients seeking meaningful results. It offers balance between efficacy and side effect management. Some patients may prefer this conservative approach.

The 9 mg dose delivered intermediate results. Participants lost an average of 64.3 pounds. This translated to 25.9% reduction from baseline. The middle dose provides another option. Physicians may titrate based on individual response. Flexibility across doses enhances clinical utility.

Extended Study Reveals Continued Weight Loss

Participants with baseline BMI above 35 qualified for extension. This subset continued treatment beyond 80 weeks. They reached 104 weeks total treatment duration. Weight loss continued during the extension phase. Participants did not plateau at 80 weeks.

The extended cohort lost up to 85.0 pounds on average. This represented 30.3% reduction at 104 weeks. The findings suggest durability of response. Longer treatment produces greater benefits. Sustained weight loss improves health outcomes significantly.

These results challenge previous treatment expectations. Traditional weight loss medications often show diminishing returns. Retatrutide appears to maintain efficacy over time. The two-year data supports chronic disease management. Obesity requires ongoing intervention, not short-term solutions.

Safety Profile and Adverse Events

Lilly reported tolerability consistent with the drug class. The 12 mg dose produced 42.4% incidence of nausea. Vomiting occurred in 25.3% of participants. These gastrointestinal effects typically diminish over time. They represent expected side effects of GLP-1 receptor activation.

The lower dose demonstrated better tolerability. Discontinuation rates remained below those at higher doses. Physicians can tailor treatment to patient preferences. Some individuals prioritize maximum efficacy. Others value minimal side effects more highly.

The trial assessed cardiometabolic health measures. Retatrutide improved multiple parameters beyond weight. Blood sugar control, blood pressure, and lipid profiles showed enhancement. These benefits reduce cardiovascular disease risk. Comprehensive health improvement justifies treatment selection.

Expert Perspectives on Clinical Significance

Dr. Ania Jastreboff served as lead investigator. She holds positions at Yale School of Medicine. Dr. Jastreboff directs the Yale Obesity Research Center. She also leads the Y-Weight program. Her expertise shapes obesity treatment paradigms nationally.

Dr. Jastreboff emphasized the chronic nature of obesity. She noted patients deserve sophisticated treatment options. The disease involves complex neurometabolic pathways. Simple behavioral interventions often prove insufficient. Medications targeting multiple mechanisms offer comprehensive solutions. Retatrutide addresses the biological complexity of obesity.

The trial validates multi-hormone approaches. Simultaneously activating three pathways produces superior results. Single-target medications leave therapeutic potential untapped. The triple agonist design maximizes weight loss. It mirrors the body’s intricate metabolic regulation systems.

Implications for Obesity Treatment Landscape

Retatrutide’s performance sets new benchmarks. The 30% weight loss threshold matters significantly. This level previously required surgical intervention. Pharmacological achievement of such results transforms treatment. More patients may access effective therapy without surgery.

Eli Lilly awaits regulatory approval for the drug. It remains investigational at present. The company runs a global registrational program. Additional studies evaluate various populations. Regulatory submissions will follow complete data analysis.

Competition in obesity treatment intensifies rapidly. Multiple pharmaceutical companies pursue advanced therapies. The market recognizes obesity’s massive health burden. Effective treatments address a critical unmet need. Retatrutide positions Eli Lilly strongly in this space.

Looking Ahead to Clinical Availability

The TRIUMPH-1 success advances retatrutide toward approval. Lilly must complete regulatory filings. The FDA will review comprehensive trial data. European and other regulatory authorities will conduct parallel assessments. Timeline to market availability remains uncertain.

Physicians anticipate multiple dosing options. The three-tier approach allows personalized treatment. Patient preferences and tolerability guide selection. Initial dosing likely starts conservatively. Escalation proceeds based on individual response.

The findings underscore modern obesity understanding. Current science views obesity as chronic neurometabolic disease. It requires sophisticated therapeutic approaches. Retatrutide represents the next generation of treatment. Its performance validates continued research investment. Patients living with obesity gain new hope for meaningful intervention.

The post Lilly’s Retatrutide Shows Dramatic Weight Loss in Phase 3 Obesity Trial appeared first on The Daily Update.

A daily tablet designed to help people maintain weight loss after stopping obesity injections has shown promising results. The medication, called orforglipron, could offer an alternative for patients worried about regaining weight. Many people stop using popular GLP-1 treatments such as Wegovy and Mounjaro due to various concerns. Researchers conducted a year-long study involving 376 participants in the United States. The findings suggest a potential solution to weight rebound issues.

The trial tested patients who had previously lost weight using injectable obesity medications. All participants had stopped their injections before beginning the oral medication trial. Manufacturer Eli Lilly funded the research. The company published results in the journal Nature Medicine. Researchers compared patients taking the new tablet against those receiving a placebo.

Significant Weight Retention Demonstrated in Trial

Patients taking orforglipron retained more than 70% of their earlier weight loss. The placebo group retained roughly 38% to 50% of their weight loss. Researchers described this difference as substantial. The study addressed a major challenge linked to GLP-1 drugs. Patients often regain weight after ending treatment with these medications. Weight rebound has become a significant concern for both doctors and patients.

The oral medication works by mimicking hormones that reduce appetite naturally. Users feel full for longer periods after eating smaller portions. This mechanism mirrors how injectable weight-loss medicines function in the body. The tablet format offers convenience that injections cannot match. Many patients express reluctance about using regular injections for extended periods. The pill eliminates concerns about needles and injection site reactions.

Expert Analysis Highlights Chronic Disease Nature

Dr. Marie Spreckley, a weight management researcher at the University of Cambridge, was not involved in the study. She told the BBC that long-term durability remains uncertain. “We still do not know how durable these effects will be over longer periods,” she stated. Dr. Spreckley emphasized that obesity is a chronic, relapsing disease. The condition often requires ongoing treatment and support throughout a patient’s life.

Her comments reflect growing medical consensus about obesity as a complex health condition. Simple lifestyle changes alone prove insufficient for many patients. Pharmaceutical interventions represent one component of comprehensive treatment strategies. The medication addresses biological factors that contribute to weight regain. Hormonal signals and metabolic changes often work against sustained weight loss.

Side Effects Remain Mild and Manageable

Side effects reported during the trial included nausea, constipation and diarrhea. Researchers described most symptoms as mild in severity. These side effects mirror those seen with injectable GLP-1 medications. Patients typically experience digestive symptoms when starting treatment. Many symptoms decrease or disappear as the body adjusts to the medication. The safety profile appears comparable to existing obesity treatments.

Medical professionals monitor patients closely during initial treatment phases. Doctors can adjust dosages if side effects become problematic. Most participants in the study continued taking the medication throughout the trial. This suggests acceptable tolerability for the majority of users. The benefit-to-risk ratio appears favorable based on current evidence.

Additional Health Benefits Beyond Weight Loss

Dr. Simon Cork of Anglia Ruskin University called the findings “a really important study.” He noted improvements in blood pressure, cholesterol and blood sugar levels. These health benefits appeared to continue in patients taking the oral medication. The ongoing improvements distinguish this medication from simple weight maintenance strategies. Metabolic health markers showed sustained positive changes throughout the study period.

Health experts say maintaining these benefits long-term could help lower obesity-related risks. Heart disease represents one major concern linked to excess weight. Diabetes, stroke and certain cancers also correlate with obesity. The medication may help reduce these serious health threats. Improved metabolic markers suggest comprehensive health benefits beyond weight numbers alone.

Market Availability and Future Accessibility

Pricing details for potential markets have not yet been announced publicly. The drug could eventually become available in the United Kingdom pending regulatory approval. UK health authorities would need to evaluate safety and efficacy data independently. Approval processes typically require extensive review of clinical trial results. Regulators assess whether benefits outweigh potential risks for the target population.

Insurance coverage will likely vary based on individual policies and regional healthcare systems. Cost considerations may affect patient access to the medication. Pharmaceutical companies often negotiate pricing with healthcare providers and government agencies. Affordability remains a significant concern for many patients seeking obesity treatment.

Treatment Strategy Implications for Patients

The new oral medication could enable a two-phase treatment approach. Patients might start with injections for initial weight loss efforts. They could then transition to the oral medication for maintenance purposes. This approach may prove more convenient and sustainable long-term. The tablet format eliminates injection-related concerns for many patients.

Doctors could tailor treatment plans based on individual patient needs and preferences. Some patients may prefer injections despite the inconvenience factor. Others will welcome an oral alternative that fits more easily into daily routines. Personalized medicine approaches recognize that different patients respond better to different treatment modalities. The availability of multiple options enhances overall treatment success rates.

Addressing Obesity as Public Health Priority

Obesity rates continue rising in many developed nations worldwide. The condition affects quality of life and overall health outcomes significantly. Medical costs associated with obesity-related conditions burden healthcare systems substantially. Effective treatments could reduce both human suffering and economic impacts. The medication represents one tool among many needed to address obesity comprehensively.

Public health experts advocate for multifaceted approaches combining medication, lifestyle modification and supportive care. No single intervention solves the complex challenge of obesity management. Research into new treatments continues advancing medical understanding of weight regulation. Scientists work to develop increasingly effective and convenient therapeutic options. The orforglipron study contributes valuable data to this ongoing effort.

The post Daily Weight Loss Pill Shows Promise After Stopping Fat Jabs appeared first on The Daily Update.

A new daily pill could help people maintain their weight loss after stopping obesity injections. The drug, called orforglipron, has shown promising results in a landmark clinical trial. Researchers say it offers an effective and affordable alternative to injectable treatments. The findings have generated significant excitement across the global medical community.

The trial was presented at the European Congress on Obesity 2026 in Istanbul. Researchers published the study in the journal Nature Medicine. Eli Lilly, the manufacturer of the weight-loss jab Mounjaro, funded the research. The study marks a potential turning point in long-term obesity care.

One major challenge with GLP-1 injections is the risk of regaining weight after stopping. Previous studies found that patients typically regained two-thirds of lost weight within a year of stopping jabs. This new trial suggests that orforglipron could significantly reduce that rebound. Experts say the implications for public health are substantial.

What the Trial Found

The trial followed 376 patients in the United States who had already been on GLP-1 injections for 72 weeks. Those patients had been using either tirzepatide (sold as Mounjaro) or semaglutide (sold as Wegovy). They then switched to either a daily orforglipron tablet or a placebo for one year. Neither group knew which treatment they received.

Among patients who had previously used tirzepatide, those on orforglipron maintained 74.7% of their weight loss. The placebo group maintained only 49.2% of their earlier loss. For former semaglutide users, the pill group kept 79.3% of their weight off. The placebo group, by comparison, retained just 37.6%.

Beyond weight retention, the drug also sustained other health improvements. Participants on orforglipron maintained better blood pressure, cholesterol, and blood sugar levels. These are critical markers for cardiovascular and metabolic health. Researchers highlighted these additional benefits as particularly meaningful.

How the Drug Works

Orforglipron belongs to a class of drugs known as GLP-1 agonists. It works by lowering blood sugar levels and slowing food digestion. The drug also reduces appetite, helping patients feel full for longer. Crucially, patients take it as a once-daily tablet rather than an injection.

This oral format could make treatment far more accessible. Many patients find injections burdensome due to storage requirements, travel restrictions, and personal preference. The availability of an oral option could open treatment to a much wider group. Experts say this distinction matters greatly for long-term adherence.

Dr. Marie Spreckley, research programme manager at the University of Cambridge, praised the study’s real-world relevance. She said the trial reflected a “highly realistic clinical scenario.” She noted that many patients avoid injectable therapy due to cost, convenience, or personal preference. A viable oral transition option could therefore reshape long-term obesity care pathways.

Expert Reactions and Medical Context

Dr. Louis Aronne, director of the Comprehensive Weight Control Center at Weill Cornell Medicine, called the findings significant. He argued that physicians should treat obesity more like other chronic diseases. “The beauty of treating obesity is you are treating all of these things,” he said. He added that effective obesity treatment eliminates the need to separately address cardiovascular risk factors.

About 30% of adults in the United Kingdom currently live with obesity. Those on Wegovy or Mounjaro take around seven medications for related health conditions on average. Treating obesity effectively could therefore reduce the overall medication burden. This has major implications for national health systems like the NHS.

However, researchers caution that more long-term data is still needed. Scientists do not yet know how durable the effects will be beyond the one-year trial period. Some experts suggest patients may need to remain on treatment indefinitely. Dr. Spreckley stressed that obesity is a chronic, relapsing condition that demands sustained management.

Cost and Availability

One of orforglipron’s most attractive features is its lower manufacturing cost. The drug costs approximately $149 per month in the United States at the lowest dose. By contrast, some GLP-1 injections cost over $1,000 per month in the US. Experts describe orforglipron as significantly cheaper to manufacture than current injectable alternatives.

The US Food and Drug Administration approved orforglipron last month. The drug could soon launch in the United Kingdom, though its UK pricing remains unknown. The drug has not yet received a UK market license. Authorities have not yet confirmed a timeline for a decision.

Rival manufacturer Novo Nordisk also developed an oral version of its GLP-1 drug Wegovy. The US has already approved that product. A UK decision on the Novo Nordisk oral drug remains pending. Competition between the two manufacturers could further drive down prices.

What This Means for Patients

Side effects from orforglipron were common in the trial but mostly mild. Patients reported nausea, constipation, and diarrhea as the most frequent complaints. These side effects mirror those seen with injectable GLP-1 treatments. Most participants tolerated them without discontinuing the drug.

The pill format removes several barriers that injectable drugs create. Patients no longer need to refrigerate medication or manage needles. Oral treatment also reduces anxiety for those uncomfortable with self-injection. These practical advantages could improve real-world treatment completion rates significantly.

Researchers stress that orforglipron is not a cure for obesity. The drug treats a chronic condition that requires ongoing, long-term management. Scientists urge health systems to invest in sustained treatment pathways. A cheaper oral pill represents one important step in that larger effort.

The post Daily Pill Could Help Millions Keep Weight Off After Stopping Obesity Injections appeared first on The Daily Update.